Japanese dengue vaccine becomes second approved by EU

TOKYO (AFP): Japanese pharmaceutical company Takeda said the European Union had given the green light to its dengue fever vaccine, making it the second jab preventing the disease to be approved by the bloc.

Mosquito-borne dengue can cause hemorrhagic fever and infects an estimated 100 to 400 million people yearly, although over 80 per cent of cases are mild or asymptomatic, the WHO says.

Takeda Pharmaceutical said its vaccine, marketed as Qdenga, was given regulatory approval by the European Commission on Thursday (Dec 8) for people aged four and above, regardless of their virus exposure history.

Another dengue vaccine, Dengvaxia -- the world's first against the disease -- is already available in the European Union, but only for those who have had a previously confirmed infection.

Dengvaxia became the subject of controversy in 2019 when the Philippines banned it over safety concerns, claims which its maker, French pharmaceutical giant Sanofi, denies.

Qdenga was approved in Indonesia earlier this year for those aged six and up.

The number of reported dengue cases has increased more than eightfold in the last two decades, according to the World Health Organization, which says "about half of the world's population (is) now at risk".

Article type: free
User access status:
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Japan , dengue , vaccine , approval , EU


Next In Aseanplus News

No more travel curbs
Jokowi: Don’t use Asean as ‘proxy’
China looking into report of spy balloon flying over US
47 facing life term in HK security trial
Beijing and Tokyo meet over disputed islets
Opposing US military expansion plans
Junta extends martial law
More engaging online than in real life
Asean News Headlines at 9pm on Friday (Feb 3, 2023)
K-drama 'Alchemy Of Souls' star Park Eun-hye visits Malaysia with family, impressed with KL

Others Also Read